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ABSTRACT
Preimplantation Genetic Diagnosis (PGD) used in assisted reproduction techniques is designed to provide help for couples 
trying to conceive a child, as it helps deliver healthy offspring. After in vitro fertilization, material is collected from the oocyte 
(polar body), 3-day-old embryo, or increasingly often, from the trophectoderm of a blastocyst. Selection of the diagnostic 
method depends on the testing center, but methods such as aCGH (Comparative Genomic Hybridization Array) and NGS 
(Next-Generation Sequencing) are supposed to have the highest reliability and precision. This paper presents a review of 
the most important methods used in PGD, their advantages and disadvantages as well as efficacy in the procedures in 
which they are used.
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INTRODUCTION
In both the UK and the US, the first children born as 
a result of the first in vitro fertilization programs with PGD 
were born in 1990 [1]. Using this method, by 2004 approxi-
mately 1,000 children had been born [2], and by 2010 this 
number had exceeded 10,000 [3, 4]. Initially, the procedure 
was thought to be extremely complicated and associated 
with a high risk of error. Currently, advances in assisted 
reproductive technology are made extremely rapidly, and 
its efficacy has been gradually increasing. At the same time, 
many aspects of PGD are still being discussed among spe-
cialists worldwide [5].
The procedure for preimplantation genetic diagnosis 
includes a sequence of activities conducted to select a ge-
netically healthy embryo for transfer. This includes collecting 
material for a test (biopsy), preparation of genetic mate-
rial for analysis (DNA isolation and amplification), analysis 
(method selection) and result preparation and issue.
Fertility clinics currently use two types of preimplanta-
tion diagnosis, depending on indications:
1. Preimplantation Genetic Diagnosis (PGD) — used to 
determine embryo genotype, performed in couples 
with genetic abnormalities such as single-gene dis-
eases, single mutations, translocations or other gene 
abnormalities.
2. Preimplantation Genetic Screening (PGS) — used 
to determine potential aneuploidies of all 24 chro-
mosomes. Particularly performed for patients older 
than 35 (AMA, Advanced Maternal Age), those with 
repeated implantation failures (RIF), repeated miscar-
riages (RM) with normal partner karyotypes, and when 
a severe male factor (SMF) is the cause of infertility. PGS 
seeks to find embryos for transfer or to select embryos 
with a normal karyotype [6].
MATERIAL COLLECTION METHODS
Selection of material for analysis depends on indications 
(through analysis of maternal material or from both parents), 
the extent of the predicted analysis and the technical pos-
sibilities. Material for analysis is taken from polar bodies, 
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blastomeres or cells collected from the trophectoderm of 
blastocysts [4]. Recently, there have been reports on the 
possibility of collecting material from fluid in the blastocyst 
cavity and blastomeres from a morula stage embryo, after 
decompaction [7, 8].
Diagnostic methods used in PGD/PGS
Pursuant to reports by the ESHRE PGD Consortium (Eu-
ropean Society of Human Reproduction and Embryology), 
in the period 1997–2007, 27,000 cycles focused on preim-
plantation diagnosis were performed: 61% were screening 
tests for aneuploidy; 17% were diagnoses of single-gene 
diseases; 16% were for chromosomal abnormalities; 4% 
were for chromosome X-linked diseases, and 2% for sex 
selection (Figure 1). Current methods of PGD/PGS diagnosis 
use fluorescent in situ hybridization (FISH), comparative 
genomic hybridization (CGH), single nucleotide polymor-
phism (SNP) analysis, and the latest method of next gen-
eration sequencing (NGS). Direct methods supporting the 
diagnostic process include, among others, polymerase chain 
reaction (PCR) and whole genome amplification (WGA) 
[9–11]. Table 1 presents some examples of applications for 
these techniques [9]. 
Fluorescent In Situ Hybridization (FISH)
FISH is one of the oldest methods used in preimplanta-
tion diagnosis and was used for the first time in 1993 by 
Schrurs et al. to determine aneuploidy [12]. Further advances 
included its use in determining chromosomal translocations 
by Munne et al. [13]. 
FISH involves identification of chromosomes or their frag-
ments with fluorescently labelled molecular probes. Probes 
are complementary to specific DNA regions that are subject 
to hybridization under specific conditions, and the result 
of this process can be observed as fluorescent spots under 
a fluorescent microscope. FISH diagnosis is performed using 
interphase nuclei. After an embryo biopsy blastomere (or 
two) is placed in a hypotonic solution, it is then digested 
and fixed with methanol and acetic acid [14]. 
It is not possible to test a whole panel of 24 chromo-
somes during one test, as it is only feasible to use 5–9 probes 
at most, for 2–3 rounds of hybridization. Therefore, PGS–FISH 
diagnosis is limited to the most common abnormalities 
involving chromosomes 13, 15–18, 21, 22, X and Y [11]. FISH 
diagnosis is also associated with a number of doubts regard-
ing result reliability. Due to such problems as inappropriate 
blastomere fixation, probe attachment and washing away 
performed many times, as well as artefacting (poor/addi-
tional or completely nonspecific signals), this technique has 
to be passed over as imprecise and associated with a high 
risk of error. In 2007, a study was conducted on 206 patients 
subject to preimplantation diagnosis with FISH, and 202 pa-
tients in the control group, aged 35–41 years. It revealed 
a significantly lower rate of pregnancies in the first group 
(25%) compared to the control group (37%) [15]. Some of 
FISH’s disadvantages were mentioned earlier, but it is also 
less than perfect in its need for material from 3-day-old 
embryos, which can disturb their further developmental 
Table 1. Examples of applications of PGD/PGS techniques
Indications FISH aCGH SNP array NGS
Sex selection YES YES YES YES
Screening tests for aneuploidy YES/Specific locus YES YES YES
Aberrations associated with a changed number of DNA copies YES/Specific locus YES YES YES
Chromosomal rearrangements (translocations) YES/Specific locus YES* YES* YES*
Single-gene mutations NO NO YES YES
De novo mutations NO NO NO YES
Mitochondrial mutations NO NO NO YES
*changes in fragments > 6 MB; aCGH — array comparative genomic hybridization; FISH — fluorescent in situ hybridization; NGS — next generation sequencing; SNP 
— single nucleotide polymorphism
Aneuploidies
Mono-genic diseases
Chromosomal abnormalities
X-chromosome-linked diseases
Sex selection
61
17
16
4 2
Figure 1. Indications for preimplantation diagnosis
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potential, and because the number of analyzed chromo-
somes is limited. In this regard, a positive FISH result does 
not indicate a ‘healthy’ embryo [14, 15]. 
FISH is also used to determine translocations. However, 
this field of study has now been successfully replaced by 
methods that are more reliable and precise, such as SNP 
[16] and NGS [17]. 
Comparative Genomic Hybridization (CGH)
Comparative genomic hybridization was introduced in 
molecular cytogenetics in 1992 by Kalioniemi et al. [18]. This 
method is used to detect duplication or deletion of chromo-
some fragments without the need for culturing cells. The 
method is based on using standard (normal) DNA labelled 
with a fluorescent dye, and tested DNA (from a patient) 
that is also labelled with a fluorochrome. Both genomes 
are placed on a slide or metaphase plate. In this way, two 
genomes coded with different colors and cut enzymatically 
into small fragments reorganize on chromosomes using the 
rule of complementarity and competition for hybridization 
sites. All quantitative differences between them are visible 
as a predominance of one color over the other [11, 15]. The 
main disadvantage of the classic CGH method is its low 
resolution, which averages 10 Mbp, and so an improved 
version, known as array CGH (aCGH), is used in preimplan-
tation diagnosis. 
Array CGH is considered to be precise (2.9% no errors), 
highly specific (1.9% errors) and not time-consuming (analy-
sis of up to 24 h). Although it is not possible to use aCGH 
for haploid or polyploid embryo, low-grade mosaicism and 
single mutations, research has proved that a significant 
majority of embryos with such dysfunctions also have ad-
ditional disorders that can be detected with aCGH (such as 
aneuploidy), and which are not present in approximately 
0.2% of cases [19, 20].
In 2011, Alfarawati et al. were one of the first to publish 
a report on delivery of the first healthy child subjected to 
aCGH-based PGD at the embryonal stage, for unbalanced 
chromosome configuration associated with a balanced 
translocation in one of its parents [21]. Schoolcraft et al. 
demonstrated a statistically significant increase in the rate 
of embryo implantations from 46.5% to 72.2% (p < 0.001) 
for embryos that had been biopsied at the blastocyst stage, 
frozen and verified with CGH-based PGS [22]. 
Chromosomal translocations are another application for 
PGD/CGH. Reciprocal translocations involve the exchange of 
segments between non-homologous chromosomes. They 
can be balanced — there are no abnormalities — or unbal-
anced, where there is an excess or lack of some chromosome 
material. Robertsonian translocations result when the long 
arms of acrocentric chromosomes fuse (13–15, 21, 22), and 
the short arms of these chromosomes are lost. As they do 
not carry any significant genetic information, an abnormal 
genotype is not formed. Being a translocation carrier in-
creases the risk of failure by even 85%, which is due to the 
fact that the carrier produces gametes with an unbalanced 
karyotype. Therefore, PGD should include detection of trans-
locations as well as screening tests of chromosomes with 
regard to numeric abnormalities. Array CGH can successfully 
be used in PGS, but translocation detection is associated 
with limitations as it is possible to detect translocated frag-
ments that are not smaller than 6 Mb [20]. However, in their 
study Colls et al. demonstrated that in diagnosis of structural 
chromosomal abnormalities, at an early embryonic stage 
it is more effective to use aCGH than FISH; the precision of 
translocation diagnosis was assessed on detection of at least 
three translocated chromosomal fragments. This study also 
demonstrated the necessity of PGS in selecting a healthy 
embryo, as 26.4% of normal or balanced embryos dem-
onstrated aneuploidy [23]. This thesis was also confirmed 
in 2011 studies by Gutierrez-Mateo et al. — in a group of 
81 embryos diagnosed as normal or balanced with regard 
to translocations, 51 had chromosomal aneuploidy that 
disqualified embryos from transfer [24]. Similar studies with 
comparable results were also performed by Fiorentino et al. 
[25] and Pujol et al. [26].
Comparative genomic hybridization is the most com-
mon method used by research centers and there is a large 
amount of data confirming its efficacy, but according to 
ESHRE guidelines, it is still necessary to validate this method 
before it can be introduced into routine diagnosis [27].
Single nucleotide polymorphism (SNP) analysis
Single nucleotide polymorphisms are places in a ge-
nome where one nucleotide in a specific locus is differ-
ent from the others in the population. Methods using SNP 
markers utilize platforms/plates allowing for determination 
of thousands or millions of SNPs in a human population 
during a single DNA analysis. There are a large number of 
SNP methods based on hybridization, starter elongation, 
ligation or so-called invasive rupture, all of which favor the 
accessibility of this method [28]. 
In 2010, Treff et al. designed and validated a method 
to screen 24 chromosomes for aneuploidy that was based 
on SNP identification [29]. Since then, many centers have 
used this method for PGS and obtained satisfactory results.
Schoolcraft et al. considered three variables in PGS di-
agnosis: blastocyst biopsy, embryo vitrification and chromo-
some screening with SNP array. After analysis, 47.4% of blas-
tocysts (356/751) were diagnosed as euploid and qualified 
for transfer. Results were not obtained in 4.5%. Biochemical 
pregnancies were obtained in 87% (87/100), clinical pregnan-
cies with fetal heart beats in 73% (73/100). Miscarriage was 
observed in two cases — 2.7%. As a result of the combined 
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activities of a research team, a high implantation rate and low 
miscarriage rate was observed in infertile couples [30]. Stud-
ies with SNP platforms were also conducted on diagnosis of 
balanced, unbalanced and Robertsonian translocations, and 
good outcomes were observed [16]. 
Next Generation Sequencing (NGS)
Next Generation Sequencing belongs to the group of 
Massively Parallel Sequencing (MPS) methods that allow for 
parallel processing of an extremely large number of nucleic 
acid molecules. As a result of sequencing on a microspace 
scale (e.g. reaction vessels with a diameter of 3 micrometers), 
it has been possible to drastically increase the amount of 
information collected during one test, up to an entire hu-
man genome. NGS has revolutionized sequencing even more 
than microarrays revolutionized CGH. Within subsequent 
years of its existence, the costs of equipment, disposables 
and chemicals have fallen, which has increased the accessibil-
ity and popularity of its use in research and medical fields.
Currently, more than ten NGS platforms are available. 
Post-Light NGS, where semiconductor chips are used in-
stead of laser-optic systems and color reactions allowing 
for translation of genetic information directly into binary 
signals, has to be mentioned. In preimplantation diagnosis 
NGS has become a better alternative than aCGH. NGS can be 
used in fresh and frozen cycles, and it is possible to analyze 
almost all types of genetic variability. NGS is also the only 
method that allows for analysis for aneuploidy or transloca-
tion of all chromosomes and mutations responsible for any 
single-gene disease, using one biopsy and one process. 
Using next generation sequencing it is possible to study 
an entire genome with regard to different abnormalities 
such as aneuploidy, single-gene mutations or de novo muta-
tions. It is quite costly to equip a laboratory with all of the 
equipment necessary to perform NGS procedures, but this 
technology allows for performance of analyses of many 
samples at the same time, thereby reducing the costs of 
a single analysis. 
When NGS is used in PGD it is necessary to isolate the 
DNA and amplify the whole genome (from a single cell or 
several cells). Then, the material is cut into small DNA frag-
ments (of 100–200 base pairs) and placed on a 2 × 2 cm 
‘chip’. It seems incredible to place a hundred thousand DNA 
fragments from different patients on a single chip, but this 
is possible thanks to DNA barcoding [31]. A sequence of 
each fragment is then compared to a reference sequence. 
The results are prepared by a computer. 
Łukaszuk et al. used NGS to screen 24 chromosomes for 
aneuploidy in PGD [32]. This study included 45 patients with 
a history of recurrent miscarriages. A control group included 
53 patients, matched by age, reason for infertility, AMH levels 
and number of antral follicles. In a group of 252 studied em-
bryos, 142 demonstrated aneuploidy, 21 were considered to 
be non-diagnostic, and 89 had a normal karyotype. 65 trans-
fers were performed among 89 normal embryos. There were 
89 transfers in the control group. With regard to the final 
outcome, the pregnancy rate in the study group was twice 
that of the control group (84.4% vs. 41.5%, respectively). 
An analysis made using NGS was also performed for a cou-
ple carrying a Robertsonian translocation, and the whole 
process of diagnosing the translocation and aneuploidy 
of 24 chromosomes resulted in implantation of a healthy 
embryo and normal pregnancy development [17]. Similar 
findings were observed by Fiorentino et al. [33], Tan et al. 
[34] and Treff et al. who successfully used next generation 
sequencing to identify monogenic diseases [35]. 
Currently, NGS is thought to be a future and target 
technology for PGD/PGS. As a gold standard for genetics 
sequencing, it allows for the almost 100% study of an en-
tire gene/genome, and so it is possible to obtain a ‘perfect’ 
analytical result.
SUMMARY
Currently, it is known that more than 50% of embryos 
obtained under in vitro conditions have genetic abnor-
malities. This number increases to 80% in patients older 
than 40. In the majority of abnormal embryos, development 
is arrested between day 3 and day 5, but the remaining 
embryos develop until the blastocyst stage, and are then 
transferred to the uterus or frozen and used in the next cycle. 
This rate of genetic abnormality is thought to be present not 
only in cycles stimulated with in vitro fertilization, but also 
in cycles stimulated with a natural approach to conception 
(i.e. insemination) [20].
Preimplantation diagnosis combined with modern tech-
nology represents a new era of infertility treatment for cou-
ples with a chance of healthy pregnancy as early as within 
one cycle. It saves time, and the patient’s ovarian reserve. 
Additionally, it avoids the mental burden associated with 
repeated miscarriages and failures, as well as saving wear 
and tear on the woman’s body and reproductive organs.
The following conclusions can be drawn based on 
discussions and research papers presented by scientists 
worldwide: 
 Ū Fluorescent in situ hybridization has been replaced 
by more reliable technologies, such as aCGH and 
NGS, where each chromosome can be tested for 
chromosomal abnormalities;
 Ū Biopsy of 3-day-old embryos is being less and less 
frequently performed and is in fact being replaced 
by biopsy of the trophectoderm of the blastocyst; 
it is thought that the embryo blastomere is not 
representative of the entire whole genome due to 
high levels of mosaicism, and that results are often 
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non-diagnostic due to the low amount of material 
available for analysis. Thanks to the trophectoderm it 
is possible to obtain several cells with a lower chance 
of mosaicism, consequently increasing the chances 
of obtaining reliable results;
 Ū Embryos that have been successfully biopsied 
and frozen can be transferred in the next cycle; ac-
cording to various studies, freezing does not have 
a significant effect on further embryo development 
or implantation. It has also been suggested that 
primed endometrium favors better implantation 
in the next cycle;
 Ū PGD/PGS technology seems to be more and more 
associated with routine use of comparative genomic 
hybridization and next generation sequencing, and 
these methods are recommended by ESHRE. How-
ever, they have to be validated for introduction to 
routine diagnostics in fertility clinics.
There are ongoing multicenter, randomized studies 
aimed at optimizing the strategy for PGD to achieve the 
highest efficacy in infertility treatment, as well as the high-
est reliability. 
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